Dechra Pharma
Does this Upgrade present an opportunity for you?
Is it irrelevant, or will the Upgrade make the Dechra Pharma share price more attractive?
- JPMorgan starts coverage at Overweight with a target price of 3000p.
- Consensus: 7 Buys, 2 Holds, 0 Sell; Avg target: 2660p (Source: Bloomberg).
- Current share price 2576p (at time of writing).
- Will the shares turn back, or will the upgrade push them towards 3158p Aug highs?
- Shares -1.2% from 2019 highs; +26.3% from 2019 lows; +24.6% year-to date.
- Source: Bloomberg, FT, Reuters, DJ Newswires, AlphaTerminal
Trading Dechra – An Example
Let’s say you think that Dechra shares have upside potential as result of this broker upgrade. You decide to buy exposure to £10,000 worth of Dechra using a CFD, at the current price of 2576p. To do this, you need £2,000.
For the purpose of this example, let’s assume the Dechra share price rises to 3158p Aug highs (+22.5%). Your profit would be £2250 from your initial investment of £2,000.
Conversely, let’s assume you open the above position, and place a stop-loss at 5% from the current price. Dechra shares fall 5% and hit your stop-loss. Your loss would be £300.
This is provided for information purposes only. It should not be taken as a recommendation.